Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, and Ulcerative Colitis with Allocetra Immunotherapy Nes-Ziona, Israel

Enlivex Receives Notice of

Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, and

Ulcerative Colitis with Allocetra Immunotherapy

Nes-Ziona, Israel, Nov. 05,

2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company,

today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering methods

of using Allocetra , the company's immunotherapy product candidate. Upon issuance, the new patent will provide

added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory

bowel disease, Crohn's disease, and ulcerative colitis. The company expects that this new patent will be issued in the United

States in the coming months.

Oren Hershkovitz, Ph.D., CEO

of Enlivex, stated: "We are pleased with the allowance of this patent application. While we are focusing our clinical development

efforts at this stage on life-threatening diseases with high mortality rates and no effective treatments, pre-clinical data have

demonstrated the potential applicability of Allocetra in providing immune rebalancing for patients with autoimmune or inflammatory

diseases with unmet needs, such as Crohn's Disease."

Allocetra has been designed

to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined

as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with Sepsis

and COVID-19, as well as treating solid tumors by modulating such tumors' microenvironments. In preclinical models, a positive

effect of Allocetra was observed in several autoimmune and inflammatory diseases.

Enlivex is a clinical stage

immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical

for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine

Release Syndrome) and for which there are no approved treatments (unmet medical needs) such as sepsis and COVID-19, as well as

enhancement of immune activity against solid tumors in combination with CAR-T or immune checkpoint therapies. For more information,

visit http://www.enlivex.com.

Safe Harbor Statement:

This press release contains forward-looking statements, which may be identified by words such as "expects," "plans,"

"projects," "will," "may," "anticipates," "believes," "should,"

"would", "could," "intends," "estimates," "suggests," "has the

potential to" and other words of similar meaning, including statements regarding expected cash balances, market opportunities

for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA programs.

All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform

Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's

business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial

products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate

data that would support the approval or marketing of these products for the indications being studied or for other indications;

that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results

to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce

results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials

may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA product

line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional

time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive

products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.

In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological

and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's

most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements

contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to

update forward-looking statements, except as required under applicable law.

Shachar Shlosberger, CFO

Enlivex Therapeutics, Ltd.

INVESTOR RELATIONS CONTACT